参考文献/References:
[1] Atkins D,Best D,Briss PA,et al.Grading quality of evidence and strength of recommendations[J].BMJ,2004,328(7454):1490.DOI:10.1136/bmj.328.7454.1490.
[2] Li Y,Teng D,Shi X,et al.Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association:national cross sectional study[J].BMJ,2020,369:m997.DOI:10.1136/bmj.m997.
[3] Cheng HT,Xu X,Lim PS,et al.Worldwide epidemiology of diabetes-related end-stage renal disease,2000-2015[J].Diabetes Care,2021,44(1):89-97.DOI:10.2337/dc20-1913.
[4] Afkarian M,Zelnick LR,Hall YN,et al.Clinical manifestations of kidney disease among US adults with diabetes,1988-2014[J].JAMA,2016,316(6):602-610.DOI:10.1001/jama.2016.10924.
[5] de Boer IH,Rue TC,Hall YN,et al.Temporal trends in the prevalence of diabetic kidney disease in the United States[J].JAMA,2011,305(24):2532-2539.DOI:10.1001/jama.2011.861.
[6] Zhang XX,Kong J,Yun K.Prevalence of diabetic nephropathy among patients with type 2 diabetes mellitus in China:a Meta analysis of observational studies[J].J Diabetes Res,2020,2020:2315607.DOI:10.1155/2020/2315607.
[7] KDOQI.KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease[J].Am J Kidney Dis,2007,49(2 Suppl 2):S12-S154.DOI:10.1053/j.ajkd.2006.12.005.
[8] Tuttle KR,Bakris GL,Bilous RW,et al.Diabetic kidney disease:a report from an ADA Consensus Conference[J].Diabetes Care,2014,37(10):2864-2883.DOI:10.2337/dc14-1296.
[9] American Diabetes Association.(9)Microvascular complications and foot care[J].Diabetes Care,2015,38 Suppl:S58-66.DOI:10.2337/dc15-S012.
[10] Kidney Disease:Improving Global Outcomes(KDIGO)Diabetes Work Group.KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease[J].Kidney Int,2020,98(4S):S1-S115.DOI:10.1016/j.kint.2020.06.019.
[11] Vallon V,Platt KA,Cunard R,et al.SGLT2 mediates glucose reabsorption in the early proximal tubule [J].J Am Soc Nephrol,2011,22(1):104-112.DOI:10.1681/ASN.2010030246.
[12] Molitch ME,DeFronzo RA,Franz MJ,et al.Nephropathy in diabetes[J].Diabetes Care,2004,27 Suppl 1:S79-S83.DOI:10.2337/diacare.27.2007.s79.
[13] Adler AI,Stevens RJ,Manley SE,et al.Development and progression of nephropathy in type 2 diabetes:the United Kingdom Prospective Diabetes Study(UKPDS 64)[J].Kidney Int,2003,63(1):225-232.DOI:10.1046/j.1523-1755.2003.00712.x.
[14] Wu Y,Wang Y,Zhang J,et al.Early-onset of type 2 diabetes mellitus is a risk factor for diabetic nephropathy progression:a biopsy-based study[J].Aging(Albany NY),2021,13(6):8146-8154.DOI:10.18632/aging.202624.
[15] Wu B,Zhang S,Lin H,et al.Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes:a cost-effectiveness analysis[J].J Diabetes Investig,2018,9(1):152-161.DOI:10.1111/jdi.12653.
[16] American Diabetes Association.11.Microvascular complications and foot care:standards of medical care in diabetes-2021[J].Diabetes Care,2021,44 Suppl 1:S151-S167.DOI:10.2337/dc21-S011.
[17] Jun M,Ohkuma T,Zoungas S,et al.Changes in albuminuria and the risk of major clinical outcomes in diabetes:results from ADVANCE-ON[J].Diabetes Care,2018,41(1):163-170.DOI:10.2337/dc17-1467.
[18] Ohkuma T,Jun M,Chalmers J,et al.Combination of changes in estimated GFR and albuminuria and the risk of major clinical outcomes[J].Clin J Am Soc Nephrol,2019,14(6):862-872.DOI:10.2215/CJN.13391118.
[19] Parving HH,Brenner BM,McMurray JJ,et al.Cardiorenal end points in a trial of aliskiren for type 2 diabetes[J].N Engl J Med,2012,367(23):2204-2213.DOI:10.1056/NEJMoa1208799.
[20] Coresh J,Heerspink H,Sang Y,et al.Change in albuminuria and subsequent risk of end-stage kidney disease:an individual participant-level consortium meta-analysis of observational studies[J].Lancet Diabetes Endocrinol,2019,7(2):115-127.DOI:10.1016/S2213-8587(18)30313-9.
[21] Lee E,Collier CP,White CA.Interlaboratory variability in plasma creatinine measurement and the relation with estimated glomerular filtration rate and chronic kidney disease diagnosis[J].Clin J Am Soc Nephrol,2017,12(1):29-37.DOI:10.2215/CJN.05400516.
[22] 万倩,张倩,钱毅,等.肾小球滤过率评估方程在2型糖尿病患者中的应用[J].中国糖尿病杂志,2014,22(9):799-803.DOI:10.3969/j.issn.1006-6187.2014.09.009.
[23] Lu J,Mu Y,Su Q,et al.Reduced kidney function is associated with cardiometabolic risk factors,prevalent and predicted risk of cardiovascular disease in Chinese adults:results from the REACTION study[J].J Am Heart Assoc,2016,5(7):e003328.DOI:10.1161/JAHA.116.003328.
[24] Inker LA,Schmid CH,Tighiouart H,et al.Estimating glomerular filtration rate from serum creatinine and cystatin C[J].N Engl J Med,2012,367(1):20-29.DOI:10.1056/NEJMoa1114248.
[25] Chi XH,Li GP,Wang QS,et al.CKD-EPI creatinine-cystatin C glomerular filtration rate estimation equation seems more suitable for Chinese patients with chronic kidney disease than other equations[J].BMC Nephrol,2017,18(1):226.DOI:10.1186/s12882-017-0637-z.
[26] Xie D,Shi H,Xie J,et al.A validation study on eGFR equations in Chinese patients with diabetic or non-diabetic CKD[J].Front Endocrinol(Lausanne),2019,10:581.DOI:10.3389/fendo.2019.00581.
[27] Fufaa GD,Weil EJ,Nelson RG,et al.Association of urinary KIM-1,L-FABP,NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus[J].Diabetologia,2015,58(1):188-198.DOI:10.1007/s00125-014-3389-3.
[28] Satirapoj B,Pooluea P,Nata N,et al.Urinary biomarkers of tubular injury to predict renal progression and end stage renal disease in type 2 diabetes mellitus with advanced nephropathy:a prospective cohort study[J].J Diabetes Complications,2019,33(9):675-681.DOI:10.1016/j.jdiacomp.2019.05.013.
[29] Molitch ME,Steffes M,Sun W,et al.Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study[J].Diabetes Care,2010,33(7):1536-1543.DOI:10.2337/dc09-1098.
[30] Penno G,Russo E,Garofolo M,et al.Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus[J].Diabetologia,2017,60(6):1102-1113.DOI:10.1007/s00125-017-4251-1.
[31] Yokoyama H,Sone H,Oishi M,et al.Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes:the Japan Diabetes Clinical Data Management study(JDDM15)[J].Nephrol Dial Transplant,2009,24(4):1212-1219.DOI:10.1093/ndt/gfn603.
[32] Thomas MC,Macisaac RJ,Jerums G,et al.Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population(national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11)[J].Diabetes Care,2009,32(8):1497-1502.DOI:10.2337/dc08-2186.
[33] Penno G,Solini A,Bonora E,et al.Clinical significance of nonalbuminuric renal impairment in type 2 diabetes[J].J Hypertens,2011,29(9):1802-1809.DOI:10.1097/HJH.0b013e3283495cd6.
[34] 杜瑞琴,张毅,李全民,等.正常白蛋白尿的2型糖尿病肾病患者临床特点调查[J].中华糖尿病杂志,2017,9(8):494-498.DOI:10.3760/cma.j.issn.1674-5809.2017.08.006.
[35] Buyadaa O,Magliano DJ,Salim A,et al.Risk of rapid kidney function decline,all-cause mortality,and major cardiovascular events in nonalbuminuric chronic kidney disease in type 2 diabetes[J].Diabetes Care,2020,43(1):122-129.DOI:10.2337/dc19-1438.
[36] Yamanouchi M,Mori M,Hoshino J,et al.Retinopathy progression and the risk of end-stage kidney disease:results from a longitudinal Japanese Cohort of 232 patients with type 2 diabetes and biopsy-proven diabetic kidney disease[J].BMJ Open Diabetes Res Care,2019,7(1):e000726.DOI:10.1136/bmjdrc-2019-000726.
[37] He F,Xia X,Wu XF,et al.Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease:a meta-analysis[J].Diabetologia,2013,56(3):457-466.DOI:10.1007/s00125-012-2796-6.
[38] Wang J,Han Q,Zhao L,et al.Identification of clinical predictors of diabetic nephropathy and non-diabetic renal disease in Chinese patients with type 2 diabetes,with reference to disease course and outcome[J].Acta Diabetol,2019,56(8):939-946.DOI:10.1007/s00592-019-01324-7.
[39] Tong X,Yu Q,Ankawi G,et al.Insights into the role of renal biopsy in patients with T2DM:a literature review of global renal biopsy results[J].Diabetes Ther,2020,11(9):1983-1999.DOI:10.1007/s13300-020-00888-w.
[40] Tervaert TW,Mooyaart AL,Amann K,et al.Pathologic classification of diabetic nephropathy[J].J Am Soc Nephrol,2010,21(4):556-563.DOI:10.1681/ASN.2010010010.
[41] Vallon V,Thomson SC.The tubular hypothesis of nephron filtration and diabetic kidney disease[J].Nat Rev Nephrol,2020,16(6):317-336.DOI:10.1038/s41581-020-0256-y.
[42] Mise K,Hoshino J,Ueno T,et al.Prognostic value of tubulointerstitial lesions,urinary N-Acetyl-β-d-glucosaminidase,and urinary β2-microglobulin in patients with type 2 diabetes and biopsy-proven diabetic nephropathy[J].Clin J Am Soc Nephrol,2016,11(4):593-601.DOI:10.2215/CJN.04980515.
[43] Hoshino J,Furuichi K,Yamanouchi M,et al.A new pathological scoring system by the Japanese classification to predict renal outcome in diabetic nephropathy[J].PLoS One,2018,13(2):e0190923.DOI:10.1371/journal.pone.0190923.
[44] Stevens PE,Levin A.Evaluation and management of chronic kidney disease:synopsis of the kidney disease:improving global outcomes 2012 clinical practice guideline[J].Ann Intern Med,2013,158(11):825-830.DOI:10.7326/0003-4819-158-11-201306040-00007.
[45] Inker LA,Grams ME,Levey AS,et al.Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities:an individual participant data Meta-analysis in a global consortium[J].Am J Kidney Dis,2019,73(2):206-217.DOI:10.1053/j.ajkd.2018.08.013.
[46] Bragg F,Holmes MV,Iona A,et al.Association between diabetes and cause-specific mortality in rural and urban areas of China[J].JAMA,2017,317(3):280-289.DOI:10.1001/jama.2016.19720.
[47] Fox CS,Matsushita K,Woodward M,et al.Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes:a meta-analysis[J].Lancet,2012,380(9854):1662-1673.DOI:10.1016/S0140-6736(12)61350-6.
[48] Zhao Z,Huo L,Wang L,et al.Survival of Chinese people with type 2 diabetes and diabetic kidney disease:a Cohort of 12-year follow-up[J].BMC Public Health,2019,19(1):1498.DOI:10.1186/s12889-019-7859-x.
[49] Afkarian M,Sachs MC,Kestenbaum B,et al.Kidney disease and increased mortality risk in type 2 diabetes[J].J Am Soc Nephrol,2013,24(2):302-308.DOI:10.1681/ASN.2012070718.
[50] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,4(13):315-409.DOI:10.3760/cma.j.cn115791-20210223-00100.
[51] 中国心血管病风险评估和管理指南编写联合委员会.中国心血管病风险评估和管理指南[J].中华预防医学杂志,2019,53(1):13-35.DOI:10.3760/cma.j.issn.0253-9624.2019.01.004.
[52] de Zeeuw D,Remuzzi G,Parving HH,et al.Albuminuria,a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy[J].Circulation,2004,110(8):921-927.DOI:10.1161/01.CIR.0000139860.33974.28.
[53] Oshima M,Neuen BL,Li J,et al.Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes:a post hoc analysis from the CREDENCE trial[J].J Am Soc Nephrol,2020,31(12):2925-2936.DOI:10.1681/ASN.2020050723.
[54] Menne J,Ritz E,Ruilope LM,et al.The Randomized Olmesartan and Diabetes Microalbuminuria Prevention(ROADMAP)observational follow-up study:benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation[J].J Am Heart Assoc,2014,3(2):e000810.DOI:10.1161/jaha.114.000810.
[55] Cabrera CS,Lee AS,Olsson M,et al.Impact of CKD progression on cardiovascular disease risk in a contemporary UK cohort of individuals with diabetes[J].Kidney Int Rep,2020,5(10):1651-1660.DOI:10.1016/j.ekir.2020.07.029.
[56] Maqbool M,Cooper ME,Jandeleit-Dahm K.Cardiovascular disease and diabetic kidney disease[J].Semin Nephrol,2018,38(3):217-232.DOI:10.1016/j.semnephrol.2018.02.003.
[57] Yokoyama H,Araki SI,Kawai K,et al.The prognosis of patients with type 2 diabetes and nonalbuminuric diabetic kidney disease is not always poor:implication of the effects of coexisting macrovascular complications(JDDM 54)[J].Diabetes Care,2020,43(5):1102-1110.DOI:10.2337/dc19-2049.
[58] Thorn LM,Gordin D,Harjutsalo V,et al.The presence and consequence of nonalbuminuric chronic kidney disease in patients with type 1 diabetes[J].Diabetes Care,2015,38(11):2128-2133.DOI:10.2337/dc15-0641.
[59] Penno G,Solini A,Orsi E,et al.Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes:the Renal Insufficiency And Cardiovascular Events(RIACE)Italian multicentre study[J].Diabetologia,2018,61(11):2277-2289.DOI:10.1007/s00125-018-4691-2.
[60] So WY,Kong AP,Ma RC,et al.Glomerular filtration rate,cardiorenal end points,and all-cause mortality in type 2 diabetic patients[J].Diabetes Care,2006,29(9):2046-2052.DOI:10.2337/dc06-0248.
[61] Umanath K,Lewis JB.Update on diabetic nephropathy:core curriculum 2018[J].Am J Kidney Dis,2018,71(6):884-895.DOI:10.1053/j.ajkd.2017.10.026.
[62] 血液透析年发病率和病因构成[J].中国血液净化,2012,11(z1):6-9.
[63] Narres M,Claessen H,Droste S,et al.The incidence of end-stage renal disease in the diabetic(compared to the non-diabetic)population:a systematic review[J].PLoS One,2016,11(1):e0147329.DOI:10.1371/journal.pone.0147329.
[64] Yang XL,So WY,Kong AP,et al.Modified end-stage renal disease risk score for Chinese type 2 diabetic patients--the Hong Kong Diabetes Registry[J].Diabetologia,2007,50(6):1348-1350.DOI:10.1007/s00125-007-0639-7.
[65] Liao LN,Li CI,Liu CS,et al.Extreme levels of HbA1c increase incident ESRD risk in Chinese patients with type 2 diabetes:competing risk analysis in National Cohort of Taiwan Diabetes Study[J].PLoS One,2015,10(6):e0130828.DOI:10.1371/journal.pone.0130828.
[66] Liu D,Lv LL.New Understanding on the role of proteinuria in progression of chronic kidney disease[J].Adv Exp Med Biol,2019,1165:487-500.DOI:10.1007/978-981-13-8871-2_24.
[67] Jia Y,Zheng Z,Xue M,et al.Extracellular vesicles from albumin-induced tubular epithelial cells promote the M1 macrophage phenotype by targeting klotho[J].Mol Ther,2019,27(8):1452-1466.DOI:10.1016/j.ymthe.2019.05.019.
[68] Skupien J,Warram JH,Smiles AM,et al.The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease[J].Kidney Int,2012,82(5):589-597.DOI:10.1038/ki.2012.189.
[69] Jiang G,Luk A,Tam C,et al.Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with type 2 diabetes[J].Kidney Int,2019,95(1):178-187.DOI:10.1016/j.kint.2018.08.026.
[70] Chapter 2:Definition,identification,and prediction of CKD progression[J].Kidney Int Suppl(2011),2013,3(1):63-72.DOI:10.1038/kisup.2012.65.
[71] 张倩,万倩,孙丹,等.2型糖尿病患者肾小球滤过率降低的危险因素及临床意义的研究[J].中国糖尿病杂志,2015,23(8):702-705.DOI:10.3969/j.issn.1006-6187.2015.08.002.
[72] Coresh J,Turin TC,Matsushita K,et al.Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality[J].JAMA,2014,311(24):2518-2531.DOI:10.1001/jama.2014.6634.
[73] Morton JI,Liew D,McDonald SP,et al.The association between age of onset of type 2 diabetes and the long-term risk of end-stage kidney disease:a national registry study[J].Diabetes Care,2020,43(8):1788-1795.DOI:10.2337/dc20-0352.
[74] Skupien J,Smiles AM,Valo E,et al.Variations in risk of end-stage renal disease and risk of mortality in an international study of patients with type 1 diabetes and advanced nephropathy[J].Diabetes Care,2019,42(1):93-101.DOI:10.2337/dc18-1369.
[75] GBD 2017 Causes of Death Collaborators.Global,regional,and national age-sex-specific mortality for 282 causes of death in 195 countries and territories,1980-2017:a systematic analysis for the Global Burden of Disease Study 2017[J].Lancet,2018,392(10159):1736-1788.DOI:10.1016/S0140-6736(18)32203-7.
[76] Fragoso A,Mendes F,Silva AP,et al.Insulin resistance as a predictor of cardiovascular morbidity and end-stage renal disease[J].J Diabetes Complications,2015,29(8):1098-1104.DOI:10.1016/j.jdiacomp.2015.05.010.
[77] Yamanouchi M,Furuichi K,Hoshino J,et al.Nonproteinuric versus proteinuric phenotypes in diabetic kidney disease:a propensity score-matched analysis of a nationwide,biopsy-based Cohort study[J].Diabetes Care,2019,42(5):891-902.DOI:10.2337/dc18-1320.
[78] Rhee CM,Kovesdy CP,You AS,et al.Hypoglycemia-related hospitalizations and mortality among patients with diabetes transitioning to dialysis[J].Am J Kidney Dis,2018,72(5):701-710.DOI:10.1053/j.ajkd.2018.04.022.
[79] 杨超,王晋伟,杨尧政,等.贫血及慢性肾脏病对糖尿病人群心脑血管事件发生与死亡的影响[J].北京大学学报(医学版),2018,50(3):495-500.DOI:10.3969/j.issn.1671-167X.2018.03.017.
[80] Soh CH,Ul Hassan SW,Sacre J,et al.Morbidity measures predicting mortality in inpatients:a systematic review[J].J Am Med Dir Assoc,2020,21(4):462-468.e7.DOI:10.1016/j.jamda.2019.12.001.
[81] Huang YQ,Gou R,Diao YS,et al.Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy[J].J Zhejiang Univ Sci B,2014,15(1):58-66.DOI:10.1631/jzus.B1300109.
[82] Perkins BA,Bebu I,de Boer IH,et al.Risk factors for kidney disease in type 1 diabetes[J].Diabetes Care,2019,42(5):883-890.DOI:10.2337/dc18-2062.
[83] Jiang W,Wang J,Shen X,et al.Establishment and validation of a risk prediction model for early diabetic kidney disease based on a systematic review and Meta-analysis of 20 Cohorts[J].Diabetes Care,2020,43(4):925-933.DOI:10.2337/dc19-1897.
[84] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33).UK Prospective Diabetes Study(UKPDS)Group[J].Lancet,1998,352(9131):837-853.
[85] de Boer IH,DCCT/EDIC Research Group.Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study[J].Diabetes Care,2014,37(1):24-30.DOI:10.2337/dc13-2113.
[86] de Boer IH,Sun W,Cleary PA,et al.Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes[J].N Engl J Med,2011,365(25):2366-2376.DOI:10.1056/NEJMoa1111732.
[87] Ismail-Beigi F,Craven T,Banerji MA,et al.Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes:an analysis of the ACCORD randomised trial[J].Lancet,2010,376(9739):419-430.DOI:10.1016/S0140-6736(10)60576-4.
[88] Ikizler TA,Robinson-Cohen C,Ellis C,et al.Metabolic effects of diet and exercise in patients with moderate to severe CKD:a randomized clinical trial[J].J Am Soc Nephrol,2018,29(1):250-259.DOI:10.1681/ASN.2017010020.
[89] Dunkler D,Dehghan M,Teo KK,et al.Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus[J].JAMA Intern Med,2013,173(18):1682-1692.DOI:10.1001/jamainternmed.2013.9051.
[90] Ikizler TA,Burrowes JD,Byham-Gray LD,et al.KDOQI clinical practice guideline for nutrition in CKD:2020 update[J].Am J Kidney Dis,2020,76(3 Suppl 1):S1-S107.DOI:10.1053/j.ajkd.2020.05.006.
[91] Hahn D,Hodson EM,Fouque D.Low protein diets for non-diabetic adults with chronic kidney disease[J].Cochrane Database Syst Rev,2020,10(10):CD001892.DOI:10.1002/14651858.CD001892.pub5.
[92] Kelly JT,Palmer SC,Wai SN,et al.Healthy dietary patterns and risk of mortality and ESRD in CKD:a Meta-analysis of Cohort studies[J].Clin J Am Soc Nephrol,2017,12(2):272-279.DOI:10.2215/CJN.06190616.
[93] Thomas MC,Moran J,Forsblom C,et al.The association between dietary sodium intake,ESRD,and all-cause mortality in patients with type 1 diabetes[J].Diabetes Care,2011,34(4):861-866.DOI:10.2337/dc10-1722.
[94] D'Elia L,Rossi G,Schiano DC,et al.Meta-analysis of the effect of dietary sodium restriction with or without concomitant renin-angiotensin-aldosterone system-inhibiting treatment on albuminuria[J].Clin J Am Soc Nephrol,2015,10(9):1542-1552.DOI:10.2215/CJN.09110914.
[95] Lambers Heerspink HJ,Holtkamp FA,Parving HH,et al.Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers[J].Kidney Int,2012,82(3):330-337.DOI:10.1038/ki.2012.74.
[96] Ekinci EI,Clarke S,Thomas MC,et al.Dietary salt intake and mortality in patients with type 2 diabetes[J].Diabetes Care,2011,34(3):703-709.DOI:10.2337/dc10-1723.
[97] Jiang N,Huang F,Zhang X.Smoking and the risk of diabetic nephropathy in patients with type 1 and type 2 diabetes:a meta-analysis of observational studies[J].Oncotarget,2017,8(54):93209-93218.DOI:10.18632/oncotarget.21478.
[98] Staplin N,Haynes R,Herrington WG,et al.Smoking and adverse outcomes in patients With CKD:The Study of Heart and Renal Protection(SHARP)[J].Am J Kidney Dis,2016,68(3):371-380.DOI:10.1053/j.ajkd.2016.02.052.
[99] Ohkuma T,Nakamura U,Iwase M,et al.Effects of smoking and its cessation on creatinine-and cystatin C-based estimated glomerular filtration rates and albuminuria in male patients with type 2 diabetes mellitus:the Fukuoka Diabetes Registry[J].Hypertens Res,2016,39(10):744-751.DOI:10.1038/hr.2016.51.
[100] Dempsey PC,Larsen RN,Sethi P,et al.Benefits for type 2 diabetes of interrupting prolonged sitting with brief bouts of light walking or simple resistance activities[J].Diabetes Care,2016,39(6):964-972.DOI:10.2337/dc15-2336.
[101] Colberg SR,Sigal RJ,Yardley JE,et al.Physical activity/exercise and diabetes:a position statement of the American Diabetes Association[J].Diabetes Care,2016,39(11):2065-2079.DOI:10.2337/dc16-1728.
[102] Greenwood SA,Castle E,Lindup H,et al.Mortality and morbidity following exercise-based renal rehabilitation in patients with chronic kidney disease:the effect of programme completion and change in exercise capacity[J].Nephrol Dial Transplant,2019,34(4):618-625.DOI:10.1093/ndt/gfy351.
[103] Look AHEAD Research Group.Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes:a secondary analysis of the Look AHEAD randomised clinical trial[J].Lancet Diabetes Endocrinol,2014,2(10):801-809.DOI:10.1016/S2213-8587(14)70156-1.
[104] Bjornstad P,Hughan K,Kelsey MM,et al.Effect of surgical versus medical therapy on diabetic kidney disease over 5 years in severely obese adolescents with type 2 diabetes[J].Diabetes Care,2020,43(1):187-195.DOI:10.2337/dc19-0708.
[105] Liakopoulos V,Franzén S,Svensson AM,et al.Renal and cardiovascular outcomes after weight loss from gastric bypass surgery in type 2 diabetes:cardiorenal risk reductions exceed atherosclerotic benefits[J].Diabetes Care,2020,43(6):1276-1284.DOI:10.2337/dc19-1703.
[106] Singh P,Adderley N,Subramanian A,et al.The impact of bariatric surgery on incident microvascular complications in patients with type 2 diabetes:a matched controlled population-based retrospective Cohort study[J].Diabetes Care,2021,44(1):116-124.DOI:10.2337/dc20-0571.
[107] Galindo RJ,Beck RW,Scioscia MF,et al.Glycemic monitoring and management in advanced chronic kidney disease[J].Endocr Rev,2020,41(5):756-774.DOI:10.1210/endrev/bnaa017.
[108] Zelnick LR,Batacchi ZO,Ahmad I,et al.Continuous glucose monitoring and use of alternative markers to assess glycemia in chronic kidney disease[J].Diabetes Care,2020,43(10):2379-2387.DOI:10.2337/dc20-0915.
[109] Battelino T,Danne T,Bergenstal RM,et al.Clinical targets for continuous glucose monitoring data interpretation:recommendations from the international consensus on time in range[J].Diabetes Care,2019,42(8):1593-1603.DOI:10.2337/dci19-0028.
[110] DCCT/EDIC research group.Effect of intensive diabetes treatment on albuminuria in type 1 diabetes:long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study[J].Lancet Diabetes Endocrinol,2014,2(10):793-800.DOI:10.1016/S2213-8587(14)70155-X.
[111] Patel A,MacMahon S,Chalmers J,et al.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes[J].N Engl J Med,2008,358(24):2560-2572.DOI:10.1056/NEJMoa0802987.
[112] Zoungas S,Chalmers J,Neal B,et al.Follow-up of blood-pressure lowering and glucose control in type 2 diabetes[J].N Engl J Med,2014,371(15):1392-1406.DOI:10.1056/NEJMoa1407963.
[113] Agrawal L,Azad N,Bahn GD,et al.Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial(VADT)[J].Diabetologia,2018,61(2):295-299.DOI:10.1007/s00125-017-4473-2.
[114] Papademetriou V,Lovato L,Doumas M,et al.Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes[J].Kidney Int,2015,87(3):649-659.DOI:10.1038/ki.2014.296.
[115] Gerstein HC,Miller ME,Byington RP,et al.Effects of intensive glucose lowering in type 2 diabetes[J].N Engl J Med,2008,358(24):2545-2559.DOI:10.1056/NEJMoa0802743.
[116] Huang ES,Liu JY,Moffet HH,et al.Glycemic control,complications,and death in older diabetic patients:the diabetes and aging study[J].Diabetes Care,2011,34(6):1329-1336.DOI:10.2337/dc10-2377.
[117] Currie CJ,Peters JR,Tynan A,et al.Survival as a function of HbA(1c)in people with type 2 diabetes:a retrospective cohort study[J].Lancet,2010,375(9713):481-489.DOI:10.1016/S0140-6736(09)61969-3.
[118] Perkovic V,Heerspink HL,Chalmers J,et al.Intensive glucose control improves kidney outcomes in patients with type 2 diabetes[J].Kidney Int,2013,83(3):517-523.DOI:10.1038/ki.2012.401.
[119] Wong MG,Perkovic V,Chalmers J,et al.Long-term benefits of intensive glucose control for preventing end-stage kidney disease:ADVANCE-ON[J].Diabetes Care,2016,39(5):694-700.DOI:10.2337/dc15-2322.
[120] Beck RW,Bergenstal RM,Riddlesworth TD,et al.Validation of time in range as an outcome measure for diabetes clinical trials[J].Diabetes Care,2019,42(3):400-405.DOI:10.2337/dc18-1444.
[121] Wanner C,Inzucchi SE,Lachin JM,et al.Empagliflozin and progression of kidney disease in type 2 diabetes[J].N Engl J Med,2016,375(4):323-334.DOI:10.1056/NEJMoa1515920.
[122] Cherney D,Zinman B,Inzucchi SE,et al.Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease:an exploratory analysis from the EMPA-REG OUTCOME randomised,placebo-controlled trial[J].Lancet Diabetes Endocrinol,2017,5(8):610-621.DOI:10.1016/S2213-8587(17)30182-1.
[123] Neal B,Perkovic V,Mahaffey KW,et al.Canagliflozin and cardiovascular and renal events in type 2 diabetes[J].N Engl J Med,2017,377(7):644-657.DOI:10.1056/NEJMoa1611925.
[124] Perkovic V,Jardine MJ,Neal B,et al.Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J].N Engl J Med,2019,380(24):2295-2306.DOI:10.1056/NEJMoa1811744.
[125] Akinci B.Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J].N Engl J Med,2019,380(19):1881.DOI:10.1056/NEJMc1902837.
[126] Heerspink H,Stefánsson BV,Correa-Rotter R,et al.Dapagliflozin in patients with chronic kidney disease[J].N Engl J Med,2020,383(15):1436-1446.DOI:10.1056/NEJMoa2024816.
[127] Mann J,ørsted DD,Brown-Frandsen K,et al.Liraglutide and renal outcomes in type 2 diabetes[J].N Engl J Med,2017,377(9):839-848.DOI:10.1056/NEJMoa1616011.
[128] Marso SP,Bain SC,Consoli A,et al.Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J].N Engl J Med,2016,375(19):1834-1844.DOI:10.1056/NEJMoa1607141.
[129] Tuttle KR,Lakshmanan MC,Rayner B,et al.Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease(AWARD-7):a multicentre,open-label,randomised trial[J].Lancet Diabetes Endocrinol,2018,6(8):605-617.DOI:10.1016/S2213-8587(18)30104-9.
[130] Gerstein HC,Colhoun HM,Dagenais GR,et al.Dulaglutide and renal outcomes in type 2 diabetes:an exploratory analysis of the REWIND randomised,placebo-controlled trial[J].Lancet,2019,394(10193):131-138.DOI:10.1016/S0140-6736(19)31150-X.
[131] Buse JB,Wexler DJ,Tsapas A,et al.2019 update to:management of hyperglycaemia in type 2 diabetes,2018.A consensus report by the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)[J].Diabetologia,2020,63(2):221-228.DOI:10.1007/s00125-019-05039-w.
[132] Neuen BL,Young T,Heerspink H,et al.SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes:a systematic review and meta-analysis[J].Lancet Diabetes Endocrinol,2019,7(11):845-854.DOI:10.1016/S2213-8587(19)30256-6.
[133] Heerspink H,Karasik A,Thuresson M,et al.Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice(CVD-REAL 3):a multinational observational cohort study[J].Lancet Diabetes Endocrinol,2020,8(1):27-35.DOI:10.1016/S2213-8587(19)30384-5.
[134] Hamblin PS,Wong R,Ekinci EI,et al.SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission[J].J Clin Endocrinol Metab,2019,104(8):3077-3087.DOI:10.1210/jc.2019-00139.
[135] Wang X,Zhang H,Zhang Q,et al.Exenatide and renal outcomes in patients with type 2 diabetes and diabetic kidney disease[J].Am J Nephrol,2020,51(10):806-814.DOI:10.1159/000510255.
[136] Kristensen SL,Rørth R,Jhund PS,et al.Cardiovascular,mortality,and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes:a systematic review and meta-analysis of cardiovascular outcome trials[J].Lancet Diabetes Endocrinol,2019,7(10):776-785.DOI:10.1016/S2213-8587(19)30249-9.
[137] Palmer SC,Tendal B,Mustafa RA,et al.Sodium-glucose cotransporter protein-2(SGLT-2)inhibitors and glucagon-like peptide-1(GLP-1)receptor agonists for type 2 diabetes:systematic review and network meta-analysis of randomised controlled trials[J].BMJ,2021,372:m4573.DOI:10.1136/bmj.m4573.
[138] Holman RR,Paul SK,Bethel MA,et al.10-year follow-up of intensive glucose control in type 2 diabetes[J].N Engl J Med,2008,359(15):1577-1589.DOI:10.1056/NEJMoa0806470.
[139] Crowley MJ,Diamantidis CJ,McDuffie JR,et al.Clinical outcomes of metformin use in populations with chronic kidney disease,congestive heart failure,or chronic liver disease:a systematic review[J].Ann Intern Med,2017,166(3):191-200.DOI:10.7326/M16-1901.
[140] Charytan DM,Solomon SD,Ivanovich P,et al.Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease[J].Diabetes Obes Metab,2019,21(5):1199-1208.DOI:10.1111/dom.13642.
[141] Lalau JD,Kajbaf F,Bennis Y,et al.Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A,3B,or 4[J].Diabetes Care,2018,41(3):547-553.DOI:10.2337/dc17-2231.
[142] van der Molen AJ,Reimer P,Dekkers IA,et al.Post-contrast acute kidney injury.Part 2:risk stratification,role of hydration and other prophylactic measures,patients taking metformin and chronic dialysis patients:recommendations for updated ESUR Contrast Medium Safety Committee guidelines[J].Eur Radiol,2018,28(7):2856-2869.DOI:10.1007/s00330-017-5247-4.
[143] Rosenstock J,Perkovic V,Johansen OE,et al.Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk:the CARMELINA randomized clinical trial[J].JAMA,2019,321(1):69-79.DOI:10.1001/jama.2018.18269.
[144] Cornel JH,Bakris GL,Stevens SR,et al.Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes:outcomes from TECOS[J].Diabetes Care,2016,39(12):2304-2310.DOI:10.2337/dc16-1415.
[145] Mosenzon O,Leibowitz G,Bhatt DL,et al.Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 Trial[J].Diabetes Care,2017,40(1):69-76.DOI:10.2337/dc16-0621.
[146] Inoue T,Shibahara N,Miyagawa K,et al.Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure[J].Clin Nephrol,2003,60(2):90-95.DOI:10.5414/cnp60090.
[147] Zhou Y,Huang Y,Ji X,et al.Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus:a Meta-analysis[J].J Clin Endocrinol Metab,2020,105(5):dgz252.DOI:10.1210/clinem/dgz252.
[148] Rave K,Heise T,Pfützner A,et al.Impact of diabetic nephropathy on pharmacodynamic and Pharmacok